(Q34185077)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

review article

1 reference

title

Tumour therapy with radionuclides: assessment of progress and problems (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author

Eva Forssell-Aronsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

Jörgen Carlsson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Sven Ola Hietala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Torgny Stigbrand

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Jan Tennvall

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy and Oncology

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

107-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648782%20AND%20SRC:MED&resulttype=core&format=json

Generating improved single-chain Fv molecules for tumor targeting

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Growth factors and their receptors: new targets for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Low-energy electron emitters for targeted radiotherapy of small tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The molecular biology of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Experimental radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Conjugate chemistry and cellular processing of EGF-dextran

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Somatostatin and somatostatin analogues: diagnostic and therapeutic uses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Detection of novel gene expression in paraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Monoclonal antibody therapy in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Receptor targeting for tumor localisation and therapy with radiopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radionuclide cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Biophysical aspects of Auger processes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Status of radioimmunotherapy in the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Haemodynamic and Transport Barriers to the Treatment of Solid Tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Arrays for protein expression profiling: towards a viable alternative to two-dimensional gel electrophoresis?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Low-dose hypersensitivity: current status and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Antibody therapy of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Positron emission tomography and radioimmunotargeting--general aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Novel therapeutic approaches to cancer patients with bone metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

An introduction to arrays

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

1 reference

7 January 2021

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Apoptosis induced by low-dose and low-dose-rate radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radiation-induced bystander effects: past history and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Effects of dextranation on the uptake of peptides in micrometastases: studies on binding of EGF in tumor spheroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Targeted radiotherapy using Auger electron emitters

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

1 reference

7 January 2021

Treatment of medullary thyroid carcinoma: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Non-targeted effects of radiation: bystander responses in cell and tissue models

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Amplification of oncogenes revisited: from expression profiling to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Twenty years with monoclonal antibodies: State of the art--Where do we go?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Biomarker conservation in primary and metastatic epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Peptide and protein PEGylation: a review of problems and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Antibody-targeted immunotherapy for treatment of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Monoclonal antibody therapy of human gliomas: current status and future approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Development of new biotin/streptavidin reagents for pretargeting

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Tools for pretargeted radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Relative biological effectiveness of accumulated 125IdU and 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021

Radionuclides and carrier molecules for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2802%2900374-2

7 January 2021